Eric Schoenmakers

Eric Schoenmakers

Analyst-Equity chez Point Sur Investors LLC

Consumer Services
Commercial Services
Finance

Profil

Dr. Eric Schoenmakers is an Equity Research Senior Analyst at Point Sur Investors LLC.
Dr. Schoenmakers worked as an independent consultant providing services across his wide spectrum of expertise, including Preclinical R&D, Translational Medicine, Biomarker and CDx Development, and GxP/Quality Management.
Before that he served as a Director Clinical Genetics within the Translational Medicine team at Pharmacyclics, Inc. Prior to joining Pharmacyclics, he headed the Pfizer Oncology Clinical Research Laboratory at Pfizer’s Global R&D site in La Jolla, CA.
He started his career in academia, and was a tenured faculty member at the Department of Human Genetics in Nijmegen, The Netherlands for over a decade.
He earned a MSc.
in Biology (with majors in Molecular Biology, Genetics, and Immunology) at the University of Nijmegen, The Netherlands, and a summa cum laude doctorate in Human (Cancer) Genetics from the University of Leuven, Belgium.

Postes actifs de Eric Schoenmakers

SociétésPosteDébut
Analyst-Equity -
Tous les postes actifs de Eric Schoenmakers

Anciens postes connus de Eric Schoenmakers

SociétésPosteFin
Corporate Officer/Principal 01/05/2016
Corporate Officer/Principal 01/11/2012
Voir l'expérience en détail de Eric Schoenmakers

Formation de Eric Schoenmakers

Radboud University Nijmegen Graduate Degree
Leuven University College Doctorate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Eric Schoenmakers

Relations

7

Relations au 1er degré

5

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées3

Commercial Services

Finance

Health Technology

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Eric Schoenmakers
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT